Latest Oligodendroglioma Stories
CALGARY, April 17, 2015 /PRNewswire/ - Oncolytics Biotech Inc.
RnRMarketResearch.com adds “Oligodendroglioma – Pipeline Review, H2 2014” report to its store.
RnRMarketResearch.com adds “Malignant Glioma – Pipeline Review, H1 2015” report to its store.
CALGARY, Feb. 9, 2015 /PRNewswire/ - Oncolytics Biotech Inc.
Planned interim analysis demonstrates the EF-14 Phase III trial met its endpoints of progression-free survival and overall survival ST. HELIER, Jersey, Dec.
Data presented today as a late-breaking abstract at the Society for Neuro-Oncology 2014 Annual Meeting in Miami demonstrated the EF-14 trial met its primary endpoint of progression-free survival and
VAL-083 Anti-tumor Activity Is Consistently Superior to Temozolomide in Preclinical Models of Glioblastoma VANCOUVER, British Columbia, MENLO PARK, Calif., and MIAMI, Nov.
("Leading Edge" Gamma Knife Treatment, led by Christopher Duma, M.D., FACS and his team of researchers, offers hope to patients with Glioblastoma Multiforme) NEWPORT BEACH, Calif.,
Single agent NKTR-102 exceeds primary endpoint with fifty-five percent of patients achieving six-week progression-free survival and fifteen percent of patients achieving partial response
- A person in a secondary role, specifically the second most important character (after the protagonist).